This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the FDA Approval of Cleveland Diagnostics' IsoPSA® Blood-Based Prostate Cancer Test
Ticker(s): CLEVELAND DIAGNOSTICS, OPK, DHR, MXDHF, TECH, HOLX, Lynx Dx, Beckman Coulter Life SciencesWho's the expert?
Institution: Cleveland Clinic
- Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine of the Cleveland Clinic.
- Currently manages >100 prostate cancer pts
- Clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials.
Interview GoalTo gain a deeper understanding of Cleveland Diagnostics' IsoPSA® Blood-Based Prostate Cancer Test
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
